FULVICIN P/G 165 Drug Patent Profile
Which patents cover Fulvicin P/g 165, and when can generic versions of Fulvicin P/g 165 launch?
Fulvicin P/g 165 is a drug marketed by Chartwell Rx and is included in one NDA.
The generic ingredient in FULVICIN P/G 165 is griseofulvin, ultramicrosize. Seven suppliers are listed for this compound. Additional details are available on the griseofulvin, ultramicrosize profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fulvicin P/g 165
A generic version of FULVICIN P/G 165 was approved as griseofulvin, ultramicrosize by MOUNTAIN on January 9th, 2014.
US Patents and Regulatory Information for FULVICIN P/G 165
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chartwell Rx | FULVICIN P/G 165 | griseofulvin, ultramicrosize | TABLET;ORAL | 061996-003 | Apr 6, 1982 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
